Aura Biosciences Inc ( (AURA) ) has shared an announcement.
On March 31, 2025, Aura Biosciences expanded its Board of Directors by appointing Teresa Marie Bitetti as a Class II director. Bitetti, who is the President of the Global Oncology Business Unit at Takeda, brings extensive operational and commercial experience to the board. Her appointment is expected to strengthen Aura’s strategic direction as it advances its clinical pipeline in ocular and urologic oncology. Bitetti’s industry expertise is anticipated to support Aura’s mission to grow as an innovative global oncology company.
More about Aura Biosciences Inc
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA.
YTD Price Performance: -31.36%
Average Trading Volume: 230,684
Technical Sentiment Signal: Buy
Current Market Cap: $294.3M
Learn more about AURA stock on TipRanks’ Stock Analysis page.